in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study ...

Find out all about the first two FDA drug approvals for the rare genetic disorder Niemann-Pick disease type C.

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced positive topline results from pivotal Study BHV4157-206-RWE (NCT06529146) demonstrating the efficacy of troriluzole on the mean ...

The pivotal BHV4157-206-RWE study evaluating Biohaven's pipeline candidate, troriluzole, for treating spinocerebellar ataxia meets its primary endpoint.

While it was just last week that Zevra Therapeutics’ Miplyffa became the first FDA-approved treatment for the lysosomal ...

The FDA approved IntraBio Inc.'s Aqneursa (levacetylleucine) yesterday for the treatment of ultra rare neurodegenerative ...

The US biotech’s neurological drug candidate showed a reduction in disease progression of at least 50% and the company will ...

Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with ...